Patented Biologics and Section 104A: No Process Disclosure Without Proving Product Identity

An image with the title "Biosimilars & Section 104A" written in a mixed-font, ransom-note style on a blue background. To the right, various colorful pills and tablets are spilling out of an orange prescription pill bottle. Featured image for article: Patented Biologics and Section 104A: No Process Disclosure Without Proving Product Identity

Roche sued Zydus for infringing its process patent on Pertuzumab. The Delhi High Court held that Roche had not shown Zydus’s biosimilar was identical to its product. Without identity, Section 104A did not apply, and the Court refused to compel Zydus to disclose its manufacturing process.

Read more about Patented Biologics and Section 104A: No Process Disclosure Without Proving Product Identity

Risdiplam – Spinal Muscular Atrophy Case: Delhi HC Favors Public Health Over Roche Patent

Delhi High Court Denies Injunction on SMA Drug Patent, Prioritises Public Interest Over Patent Rights Featured image for article: Risdiplam – Spinal Muscular Atrophy Case: Delhi HC Favors Public Health Over Roche Patent

The Delhi High Court, in a significant ruling dated March 24th, 2024, rejected the interim injunction application of F Hoffmann-La Roche AG (“Roche”) against Natco...

Read more about Risdiplam – Spinal Muscular Atrophy Case: Delhi HC Favors Public Health Over Roche Patent